Clinical trial · Interventional
Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer
Study of the Interest of the Parametric Imaging in Positron Emission Tomography on the Recurrence Prognosis at One Year in Patient With Non Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the concordance between Positron E mission tomography parametric imaging versus standard PET for the 1 year prognosis of patients with NSCLC treated by radiochemotherapy. The ancillary study will evaluate the interest of parametric PET imaging during the treatment (around 42 Gray) to detect the local relapse of the lesion in order to propose a treatment re-planification or intensification (not realized on the present study).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Parametric Imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Parametric Imaging
- description
- one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy. Two PET scans at 3 months and one year after inclusion
- interventionNames
- Procedure: Parametric Imaging
Primary outcomes (1)
- measure
- Prognosis of recurrence
- timeFrame
- one year
- description
- Comparison between parametric Imaging and standard Imaging in PET for the diagnosis of recurrence
Secondary outcomes (2)
- measure
- analysis method of Parametric Imaging quantification determination
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female patient * Age over 18 years old * Histological evidence of non-small cell lung cancer * Treatment by curative intent radio-chemotherapy based on platinum salt * Stage superior or equal to T2a * Tumour FDG uptake higher than mediastinal background noise on FDG PET/CT * Affiliated or beneficiary of a social benefit system Exclusion Criteria: * Histology other than non-small cell lung cancer * Patient without measurable target * Absence of FDG uptake on FDG-PET/CT scan * Previous neoplastic disease of less than 2 years duration or progressive * Pregnant women or women of child-bearing potential or breast feeding mothers * World Health Organisation scale superior or equal to 2 * Adult subjects who are under protective custody or guardianship * Patient unable to comply with the specific obligations of the study (geographic, social or physical reasons) Uncontrolled diabetes with blood glucose ≥10 mmol/L, Hypersensitivity to the active substance (FDG) or to any of the excipients, Patients unable to understand the purpose of the study (language, etc.) * Unaffiliated or not beneficiary of a social benefit system
References
Publications (1)
- DERIVEDColard E, Delcourt S, Padovani L, Thureau S, Dumouchel A, Gouel P, Lequesne J, Ara BF, Vera P, Taieb D, Gardin I, Barbolosi D, Hapdey S. A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement. EJNMMI Res. 2018 Nov 15;8(1):99. doi: 10.1186/s13550-018-0454-9. PMID 30443801